Search

Your search keyword '"Burger, D. M."' showing total 359 results
Start Over Author "Burger, D. M."
359 results on '"Burger, D. M."'

3. De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study

Author

Oosterhof, P., primary, de Zoete, B. G. J. A., additional, Vanhommerig, J. W., additional, Langebeek, N., additional, Gisolf, E. H., additional, van Hulzen, A. G. W., additional, Lammers, A. J. J., additional, Weijsenfeld, A. M., additional, van der Valk, M., additional, Grintjes, K., additional, van Crevel, R., additional, van Luin, M., additional, Brinkman, K., additional, and Burger, D. M., additional

Published
2024
Full Text
View/download PDF

4. The EB Factory Project I. A Fast, Neural Net Based, General Purpose Light Curve Classifier Optimized for Eclipsing Binaries

Author

Paegert, M., Stassun, K. G., and Burger, D. M.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - Solar and Stellar Astrophysics
Abstract

We describe a new neural-net based light curve classifier and provide it with documentation as a ready-to-use tool for the community. While optimized for identification and classification of eclipsing binary stars, the classifier is general purpose, and has been developed for speed in the context of upcoming massive surveys such as LSST. A challenge for classifiers in the context of neural-net training and massive data sets is to minimize the number of parameters required to describe each light curve. We show that a simple and fast geometric representation that encodes the overall light curve shape, together with a chi-square parameter to capture higher-order morphology information results in efficient yet robust light curve classification, especially for eclipsing binaries. Testing the classifier on the ASAS light curve database, we achieve a retrieval rate of 98\% and a false-positive rate of 2\% for eclipsing binaries. We achieve similarly high retrieval rates for most other periodic variable-star classes, including RR Lyrae, Mira, and delta Scuti. However, the classifier currently has difficulty discriminating between different sub-classes of eclipsing binaries, and suffers a relatively low ($\sim$60\%) retrieval rate for multi-mode delta Cepheid stars. We find that it is imperative to train the classifier's neural network with exemplars that include the full range of light curve quality to which the classifier will be expected to perform; the classifier performs well on noisy light curves only when trained with noisy exemplars. The classifier source code, ancillary programs, a trained neural net, and a guide for use, are provided., Comment: 29 pages, 12 figures

Published
2014
Full Text
View/download PDF

5. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naive individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Author

Prins, H. A. B., Zino, L., Svensson, Elin M., Verbon, A., de Bree, G. J., Prins, J. M., Reiss, P., Burger, D. M., Rokx, C., Colbers, A., Team, NOVA Study, Prins, H. A. B., Zino, L., Svensson, Elin M., Verbon, A., de Bree, G. J., Prins, J. M., Reiss, P., Burger, D. M., Rokx, C., Colbers, A., and Team, NOVA Study

Abstract

To the authors' knowledge, there is currently no literature or guidance recommendation regard-ing whether the dose of dolutegravir (DTG) should be increased when co-administered with darunavir/ritonavir (DRV/r) in patients with acute human immunodeficiency virus infection (AHI). This study assessed the pharmacokinetics (PK) of twice-daily (BID) DTG and once-daily (QD) DRV/r, and com-pared this with DTG QD without DRV/r in patients with AHI. Forty-six participants initiated antiretro-viral therapy within < 24 h of enrolment: DTG 50 mg BID, DRV/r 80 0/10 0 mg QD, and two nucleoside reverse transcriptase inhibitors (NRTIs) for 4 weeks (Phase I); and DTG 50 mg QD with two NRTIs there-after (Phase II: reference). Total DTG trough concentration (Ctrough) and area under the concentration-time profile of 0-24 h (AUC0-24h) were predicted using a population PK model. DTG glucuronidation metabolic ratio (MR) and DTG free fraction were determined and compared per treatment phase using geometric mean ratio (GMR) and 90% confidence interval (CI). Participants had a predicted geometric mean steady-state DTG Ctrough of 2.83 [coefficient of variation (CV%) 30.3%] mg/L (Phase I) and 1.28 (CV% 52.4%) mg/L (Phase II), with GMR of 2.20 (90% CI 1.90-2.55). Total exposure during DTG BID increased but did not double [AUC0-24h GMR 1.65 (90% CI 1.50-1.81) h.mg/L]. DTG glucuronidation MR increased by approxi-mately 29% during Phase I. DTG Ctrough was above in-vivo EC90 (0.32 mg/L) during both phases, except in one participant during Phase I. At Week 8, 84% of participants had viral loads <= 40 copies/mL. The drug-drug interaction between DTG (BID) and DRV/r (QD) was due to induced glucuronidation, and is not clinically relevant in patients with AHI.(c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Published
2023
Full Text
View/download PDF

7. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Author

Prins, H. A.B., Zino, L., Svensson, E. M., Verbon, A., de Bree, G. J., Prins, J. M., Reiss, P., Burger, D. M., Rokx, C., Colbers, A., Prins, H. A.B., Zino, L., Svensson, E. M., Verbon, A., de Bree, G. J., Prins, J. M., Reiss, P., Burger, D. M., Rokx, C., and Colbers, A.

Abstract

To the authors’ knowledge, there is currently no literature or guidance recommendation regarding whether the dose of dolutegravir (DTG) should be increased when co-administered with darunavir/ritonavir (DRV/r) in patients with acute human immunodeficiency virus infection (AHI). This study assessed the pharmacokinetics (PK) of twice-daily (BID) DTG and once-daily (QD) DRV/r, and compared this with DTG QD without DRV/r in patients with AHI. Forty-six participants initiated antiretroviral therapy within <24 h of enrolment: DTG 50 mg BID, DRV/r 800/100 mg QD, and two nucleoside reverse transcriptase inhibitors (NRTIs) for 4 weeks (Phase I); and DTG 50 mg QD with two NRTIs thereafter (Phase II: reference). Total DTG trough concentration (Ctrough) and area under the concentration–time profile of 0–24 h (AUC0–24h) were predicted using a population PK model. DTG glucuronidation metabolic ratio (MR) and DTG free fraction were determined and compared per treatment phase using geometric mean ratio (GMR) and 90% confidence interval (CI). Participants had a predicted geometric mean steady-state DTG Ctrough of 2.83 [coefficient of variation (CV%) 30.3%] mg/L (Phase I) and 1.28 (CV% 52.4%) mg/L (Phase II), with GMR of 2.20 (90% CI 1.90–2.55). Total exposure during DTG BID increased but did not double [AUC0–24h GMR 1.65 (90% CI 1.50–1.81) h.mg/L]. DTG glucuronidation MR increased by approximately 29% during Phase I. DTG Ctrough was above in-vivo EC90 (0.32 mg/L) during both phases, except in one participant during Phase I. At Week 8, 84% of participants had viral loads ≤40 copies/mL. The drug–drug interaction between DTG (BID) and DRV/r (QD) was due to induced glucuronidation, and is not clinically relevant in patients with AHI.

Published
2023

8. GLP‐1 agonists for people living with HIV and obesity, is there a potential?

Author

Zino, L., Tack, C. J., Richel, O., and Burger, D. M.

Subjects
OBESITY, HIV infections, DRUG efficacy, PROTEASE inhibitors, GLYCEMIC control, ANTIRETROVIRAL agents, WEIGHT loss, HEART beat, DRUG interactions, GLUCAGON-like peptide-1 agonists, PSYCHOLOGY of HIV-positive persons
Abstract

Background and objectives: Obesity trends and metabolic dysregulation are rising in people living with HIV using antiretrovirals (ARVs). Underlying causes and preventive strategies are being investigated. Two glucagon like‐peptide 1 (GLP‐1) agonists, liraglutide and semaglutide, were formerly approved as glucose‐lowering drugs and have been recently approved for long‐term weight loss in people with obesity. Due to the lack of therapeutic guidelines or clinical trials in people with HIV, we discuss the potential benefits, safety aspects and pharmacological considerations of prescribing liraglutide and semaglutide in people with HIV. Results: Clinical experience is limited to two clinical cases of diabetic people with HIV using liraglutide after which a successful weight loss and glycaemic control were observed. None of the adverse events associated with liraglutide and semaglutide usage indicate an additional risk for people with HIV. Extra caution showed be warranted when initiating GLP‐1 agonist therapy in people with HIV taking protease inhibitors who have pre‐existing risk factors for heart rate variability to reduce the incidence of RP interval prolongation. GLP‐1 agonists are metabolized by endopeptidases, and thus do not generate major drug–drug interactions with most drugs, including ARVs. GLP‐s agonists are known to inhibit gastric acid secretion, which warrants caution and close monitoring when combined with atazanavir and oral rilpivirine, two ARVs that require low gastric pH for an optimal absorption. Conclusion: Theoretical considerations and a few available clinical observations support semaglutide and liraglutide prescription in people with HIV, with, thus far, no indications of concern regarding efficacy, safety or pharmacological interactions with ARVs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Effect of pregnancy and concomitant antiretrovirals on the pharmacokinetics of tenofovir in women with HIV receiving tenofovir disoproxil fumarate-based antiretroviral therapy versus women with HBV receiving tenofovir disoproxil fumarate monotherapy

Author

Bukkems, V. E., Smolders, E. J., Jourdain, Gonzague, Burger, D. M., Colbers, A. P., Cressey, T. R., PANNA Network, and ITAP Study Group

Subjects
fumarate, antiretroviral therapy, tenofovir disoproxil, virus diseases, HIV, hepatitis, pregnancy
Abstract

Tenofovir disoproxil fumarate (TDF) is recommended as part of antiretroviral therapy (ART) for pregnant women with HIV and as monotherapy for pregnant women with hepatitis B virus (HBV) monoinfection at high risk of transmitting infection to their infants. Tenofovir (TFV) plasma exposures are reduced during pregnancy; however, concomitant antiretrovirals and the viral infection itself can also influence TFV pharmacokinetics. Our aim was to compare TFV pharmacokinetics in pregnant women receiving TDF-based ART, with or without a ritonavir-boosted protease inhibitor (r/PI), to pregnant women with HBV receiving TDF monotherapy. Non-r/PI regimens were primarily integrase strand transfer inhibitors or nonnucleoside reverse transcriptase inhibitor-based regimens. Data were combined from a pharmacokinetic study of pregnant women with HIV on ART (PANNA), and a study assessing TFV pharmacokinetics in pregnant women with HBV (iTAP). A total of 196 pregnant women, 59 with HIV (32 receiving r/PIs) and 137 with HBV monoinfection were included. Intraindividual TFV area under the plasma concentration-time curve from time 0 to 24 hours was 25%, 26%, and 21% lower during the third trimester compared to I month postpartum in women with HIV using TDF and an r/PI or TDF and non-r/PI and women with HBV receiving TDF monotherapy, respectively. TFV area under the plasma concentration-time curve from time 0 to 24 hours was similar in pregnant women receiving non-r/PI to pregnant women with HBV receiving TDF monotherapy (1.84 vs 1.86 mu g . h/mL); however, pregnant women receiving TDF with an r/PI had higher exposures (2.41 mu g . h/mL; P < .01). Pregnancy reduces TFV exposure and the relative size was not impacted by concomitant antiretroviral drugs or viral infection, but a drug-drug interaction between TDF and r/PI remains during pregnancy, leading to higher exposures than those on TDF and non-r/PI or TDF monotherapy.

Published
2021

19. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals

Author

Brüggemann, R. J., Moes, D. J.A.R., van Rhee, K. P., van 't Veer, N. E., Koch, B. C.P., van Rossum, M., Windsant - van den Tweel, A. Vermeulen, Reijers, M. H.E., van Kimmenade, R. R.J., Rahamat-Langedoen, J. C., Rettig, T. C.D., van Raalte, R., van Paassen, J., Polderman, F. N., van der Linden, P. D., Frenzel, T., de Mast, Q., Burger, D. M., Schouten, J., van de Veerdonk, F. L., Pickkers, P., ter Heine, R., Brüggemann, R. J., Moes, D. J.A.R., van Rhee, K. P., van 't Veer, N. E., Koch, B. C.P., van Rossum, M., Windsant - van den Tweel, A. Vermeulen, Reijers, M. H.E., van Kimmenade, R. R.J., Rahamat-Langedoen, J. C., Rettig, T. C.D., van Raalte, R., van Paassen, J., Polderman, F. N., van der Linden, P. D., Frenzel, T., de Mast, Q., Burger, D. M., Schouten, J., van de Veerdonk, F. L., Pickkers, P., and ter Heine, R.

Published
2021

22. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection : a systematic review

Author

Jacobs, T. G., Svensson, E. M., Musiime, V., Rojo, P., Dooley, K. E., Mcilleron, H., Aarnoutse, R. E., Burger, D. M., Turkova, A., Colbers, A., Giaquinto, C, and WHO Pediatric Antiretroviral Working Group

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Infectious Medicine, Tuberculosis, Systematic Reviews, Anti-HIV Agents, 030106 microbiology, HIV Infections, Infektionsmedicin, Microbiology, Lopinavir, 03 medical and health sciences, 0302 clinical medicine, WHO Paediatric Antiretroviral Working Group, Rare Diseases, Pharmacokinetics, Internal medicine, medicine, AcademicSubjects/MED00740, Humans, Pharmacology (medical), 030212 general & internal medicine, Child, Preschool, Pharmacology, business.industry, Coinfection, Pharmacology and Pharmaceutical Sciences, medicine.disease, AcademicSubjects/MED00290, Infectious Diseases, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Pharmaceutical Preparations, Medical Microbiology, Concomitant, Child, Preschool, 6.1 Pharmaceuticals, HIV/AIDS, business, AcademicSubjects/MED00230, Infection, Co infection
Abstract

IntroductionManagement of concomitant use of ART and TB drugs is difficult because of the many drug–drug interactions (DDIs) between the medications. This systematic review provides an overview of the current state of knowledge about the pharmacokinetics (PK) of ART and TB treatment in children with HIV/TB co-infection, and identifies knowledge gaps.MethodsWe searched Embase and PubMed, and systematically searched abstract books of relevant conferences, following PRISMA guidelines. Studies not reporting PK parameters, investigating medicines that are not available any longer or not including children with HIV/TB co-infection were excluded. All studies were assessed for quality.ResultsIn total, 47 studies met the inclusion criteria. No dose adjustments are necessary for efavirenz during concomitant first-line TB treatment use, but intersubject PK variability was high, especially in children 4 weeks old as well as twice-daily dolutegravir (instead of once daily) in children older than 6 years. Exposure to some TB drugs (ethambutol and rifampicin) was reduced in the setting of HIV infection, regardless of ART use. Only limited PK data of second-line TB drugs with ART in children who are HIV infected have been published.ConclusionsWhereas integrase inhibitors seem favourable in older children, there are limited options for ART in young children (

Published
2020

24. The dolutegravir/valproic acid drug–drug interaction is primarily based on protein displacement

Author

Bollen, P D J, primary, Prins, H A B, additional, Colbers, A, additional, Velthoven-Graafland, K, additional, Rijnders, B J A, additional, de Vries-Sluijs, T E M S, additional, van Nood, E, additional, Nouwen, J, additional, Bax, H, additional, de Mendonca Melo, M, additional, Verbon, A, additional, Burger, D M, additional, and Rokx, C, additional

Published
2021
Full Text
View/download PDF

38. Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: The CELINE project

Author

Dijk, M., Kracht, P. A. M., Arends, J. E., Blokzijl, H., Burger, D. M., Erpecum, K. J., Hoek, B., Knegt, R. J., Posthouwer, D., Ramsoekh, D., Rijnders, B. J. A., Schinkel, J., Willemse, S. B., Marc van der Valk, Drenth, J. P. H., Medical Microbiology and Infection Prevention, AII - Infectious diseases, Gastroenterology and Hepatology, Infectious diseases, Amsterdam Gastroenterology Endocrinology Metabolism, APH - Digital Health, APH - Personalized Medicine, APH - Global Health, Gastroenterology & Hepatology, Internal Medicine, Med Microbiol, Infect Dis & Infect Prev, MUMC+: DA MMI Staf (9), RS: FHML non-thematic output, Gastroenterology and hepatology, and AGEM - Digestive immunity

Subjects
AMSTERDAM, OUTCOMES, DECLINE, elimination, SDG 3 - Good Health and Well-being, HCV, chronic hepatitis C, virus diseases, retrieval
Abstract

Chronic hepatitis C virus (HCV) infection is a global public health issue, which is associated with high rates of morbidity and mortality. The development of direct acting antivirals (DAAs) has transformed treatment: they offer us highly-effective therapy with superior tolerability compared to interferon-containing regimens. In 2016, the World Health Organization (WHO) therefore adopted several ambitious viral hepatitis elimination targets, aiming for a 90% reduction in new infections and a 65% reduction in mortality by 2030. The ultimate goal is to eliminate HCV completely. It is reasonable that these goals may be achieved in the Netherlands due to the low prevalence of chronic HCV, the availability of DAAs, and excellent healthcare infrastructure. This paper describes a national effort to curtail the HCV epidemic in the Netherlands through an HCV retrieval and linkage to care project (CELINE: Hepatitis C Elimination in the Netherlands).

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results